Organon (1OGN) Stock Overview
Develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
1OGN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Organon & Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.94 |
| 52 Week High | US$11.89 |
| 52 Week Low | US$4.86 |
| Beta | 1.52 |
| 1 Month Change | 1.50% |
| 3 Month Change | 1.17% |
| 1 Year Change | 32.90% |
| 3 Year Change | -30.20% |
| 5 Year Change | -58.45% |
| Change since IPO | -53.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1OGN | IT Pharmaceuticals | IT Market | |
|---|---|---|---|
| 7D | 1.0% | 0.3% | -0.01% |
| 1Y | 32.9% | 9.3% | 18.2% |
Return vs Industry: 1OGN exceeded the Italian Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: 1OGN exceeded the Italian Market which returned 18.2% over the past year.
Price Volatility
| 1OGN volatility | |
|---|---|
| 1OGN Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IT Market | 7.1% |
| 10% least volatile stocks in IT Market | 2.6% |
Stable Share Price: 1OGN has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1OGN's weekly volatility has decreased from 11% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 10,000 | Joe Morrissey | www.organon.com |
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist.
Organon & Co. Fundamentals Summary
| 1OGN fundamental statistics | |
|---|---|
| Market cap | €3.13b |
| Earnings (TTM) | €181.96m |
| Revenue (TTM) | €5.33b |
Is 1OGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1OGN income statement (TTM) | |
|---|---|
| Revenue | US$6.13b |
| Cost of Revenue | US$2.86b |
| Gross Profit | US$3.27b |
| Other Expenses | US$3.06b |
| Earnings | US$209.00m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.80 |
| Gross Margin | 53.40% |
| Net Profit Margin | 3.41% |
| Debt/Equity Ratio | 850.2% |
How did 1OGN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 21:08 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Organon & Co. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Navann Ty Dietschi | BNP Paribas |
| Jason Matthew Gerberry | BofA Global Research |